IDEAYA Biosciences, Inc.
IDYA
Rank in Stocks
#4529
IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to... IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.
Share Price
$35.50
Market Cap
$3.43B
Change (1 day)
5.00%
Change (1 year)
16.36%
Country
US
Trade IDEAYA Biosciences, Inc. (IDYA)
Category
Healthcare
Revenue for IDEAYA Biosciences, Inc. (IDYA)
Revenue in Jun 2026 TTM: $234.13M
According to IDEAYA Biosciences, Inc. latest financial reports the company's current revenue (TTM) is $234.13M. In 2023 the company made a revenue of $23.39M a decrease compared to the revenue in the year 2022 that was $50.93M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for IDEAYA Biosciences, Inc. from 2017 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $234.13M | 3,244.67% |
| 2024 | $7.00M | -70.07% |
| 2023 | $23.39M | -54.08% |
| 2022 | $50.93M | 82.28% |
| 2021 | $27.94M | 43.01% |
| 2020 | $19.54M | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $12.62B | 5,292.07% |
US
|
|
| $2.23B | 851.62% |
US
|
|
| $15.74B | 6,624.70% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 2,471.80% |
NL
|
